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Abstract
Background: Serum apolipoprotein (apo) A-I was considered to be an immune regulator and could suppress pro-
inflammatory cytokines generated by activated T cell in some autoimmune diseases. However, the change of serum 
apoA-I levels in multiple sclerosis (MS) patients is unknown.
Methods: In the presentation we performed a study on serum apoA-I levels in the patients with MS. We enrolled some 
age and gender matched patients with MS, autoimmune demyelinating diseases (Guillain-Barre Syndrome and 
Clinically Isolated Syndrome), neuroinflammatory diseases (viral encephalitis), autoimmune connective diseases 
(rheumatoid arthritis and systemic lupus erythematosus) and healthy control groups, and tested their serum lipids 
levels: total cholesterol (TC), triglyceride (TG), high-density lipoproteins (HDL), apolipoproteinB100 (apoB100), 
apolipoproteinA-I (apoA-I).
Results: For all patients, age had no effect on serum apoA-I levels (P > 0.05). Meanwhile, we proved the highest serum 
apoA-I levels in MS patients and the lowest serum apoA-I levels in SLE patients. Serum apoA-I levels was significantly 
elevated in female MS patients (P = 0.033; P < 0.05).
Conclusion: In short we believed that patients with MS and other autoimmune demyelination had significantly 
decreased serum levels of apo A-I.
Background
Some previous study suggested that apoA-I was the
major structural protein to promote lipid transfer in
human plasma, which modulated several cellular func-
tions and involved in the pathogenesis of some autoim-
mune diseases [1-9]. Hyka et al. approved that
apolipoprotein A-I (apo A-I) interfered interreaction
between monocytes and activeted T lymphocyte,
repressed activation and production of some important
pro-inflammatory cytokines in the pathogenesis of some
inflammatory and autoimmune diseases (including mul-
tiple sclerosis) [6,7].
Multiple sclerosis (MS) is an autoimmune demyelinat-
ing disease in central nervous system (CNS) [10,11], and
some cytokines secreted by T-help cell (TH1/TH2) play
the critical role in initiation and progression of MS [12-
14]. Nowadays, more and more study focused on the rela-
tionship between apoA-I and autoimmune diseases
including rheumatoid arthritis (RA), experimental colitis,
thyroiditis and systemic lupus erythematosus (SLE) [15-
18]. Although previous studies confirmed elevated serum
cholestero, low-density lipoproteins (LDL) and high-den-
sity lipoproteins(HDL) during the clinical active phase of
experimental allergic encephalomyelitis (EAE) (animal
model of MS) [18], few studies explored the effect of
apoA-I on MS. Therefore, this is the first study to investi-
gate the relationship between serum apoA-I levels and
MS patients.
Methods
In this clinic-based study, we retrospectively learned 298
hospitalized Chinese patients who had been identified
consecutively, examined, treated by our medical staff
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from January 2002 to July 2008. These patients comprised
of 60 Relapsing-Remitting MS patients (mean age, 35.9 ±
14.8 years; female-male, 32:28), 38 patients with Clini-
cally Isolated Syndrome (CIS) including optic neuritis
and myelitis (mean age, 36.0 ± 18.3 years; female-male,
19:19; myelitis: optic neuritis, 23:15), 28 patients with
Guillain-Barre Syndrome (GBS) (mean age, 36.2 ± 20.0
years; female-male, 10:18), 51 patients with viral enceph-
alitis (mean age, 30.0 ± 13.7 years; female-male, 25:26), 25
patients with rheumatoid arthritis (RA) (mean age, 36.3 ±
9.8 years; female-male, 20:16), 36 patients with systemic
lupus erythematosus (SLE) (mean age, 31.6 ± 10.7 years;
female-male, 22:14), 60 healthy subjects (mean age, 35.7 ±
10.2 years; female-male, 27:23).
In the presentation, MS patients and RA as well as SLE
patients were compared, because research had shown
that low serum levels of apoA-I in RA and SLE patients
[15,17]. We selected the patients with viral encephalitis in
order to compare serum apoA-I levels between the those
patients and MS patients. To confirmed the difference
between MS patients and other patients with central ner-
vous system autoimmune demyelinating diseases, CIS
and GBS patients were selected. Meanwhile, a number of
age-matched healthy control group were selected.
All selected patients had never received disease-modi-
fying immunosuppressive therapy that had the affect on
plasma lipid or lipoprotein levels two months before
admission. All patients were not suffering from diabetes
mellitus, liver or thyroid dysfunction, hypertensive dis-
ease, cardiovascular disease, stroke, excessive alcohol
consumption in their active phase. All MS patients had
been diagnose with MS according to the criteria of
McDonald et al [19], and scored by the Expanded Disabil-
ity Status Scale (EDSS) [20]. The mean EDSS score was
3.4 ± 1.99, range 1.0-10. The mean disease course was 5 ±
3.9 years, range 0.1-18 years. All MS patients had the
relapsing-remitting (RR) type, RA patients were defined
by the 1988 revised criteria of the American College of
Rheumatology [21], SLE patients met 1997 criteria for
SLE [22].
The blood were collected to detect serum apo A-I at 6
o'clock in the morning and no eating all over the patients
and healthy people.
Statistical analysis
All statistical analyses were performed using the Statisti-
cal Program for Social Sciences (SPSS) statistical software
(version 11.0, Chicago, IL, USA). Results were expressed
as means ± standard deviation (SD). To analyze the effect
of age, gender and different entity on serum apoA-I levels
in different groups, comparison of serum apoA-I levels
among all male or female patients, comparison of serum
apoA-I levels between male and female patients in each
group using the Multivarite ANOVA. All comparisons
were two-sided, with a P-value of less than 0.05 used to
indicate statistical significance.
Results
Table 1 shown age at onset had little effect on serum
apoA-I levels, however, different kinds of diseases (P <
0.001) and gender (P < 0.05) have different levels of
serum, therefore, we first compared apoA-I levels in dif-
ferent disease groups not taking into account gender and
age factors. We found significantly higher serum apoA-I
levels in MS (1.392 ± 0.047 g/L) and other autoimmune
demyelinating diseases (GBS, CIS) than healthy subjects
(1.179 ± 0.047 g/L), RA (1.035 ± 0.061 g/L) and SLE
patients(1.179 ± 0.047 g/L). Serum apoA-I levels in RA
and SLE patients (P = 0.002) significantly lower than
healthy control.
In order to access the impact of gender on apoA-I, we
compared with male and female patients respectively
(Table 2). For women, healthy control (1.230 ± 0.062 g/L)
had significantly higher serum apoA-I levels than SLE
patients (0.897 ± 0.068 g/L; P < 0.001), but significantly
lower than female MS patients (1.516 ± 0.057 g/L; P =
0.001). Female patients with viral encephalitis (1.243 ±
Table 1: Analysis of serumapo A-I in the entire patients
Group*** MS CIS GBS Viral 
encephalitis
SLE RA Healthy 
controls
Gender**
(female:male)
32:28 19:19 10:18 26:25 22:14 20:15 27:32
Mean age ± 
SD*(years)
35.9 ± 14.8 36.0 ± 18.3 36.2 ± 20.0 30.0 ± 13.7 31.6 ± 10.7 36.3 ± 9.8 35.7 ± 10.2
Apo A-I (g/L) 1.392 ± 0.047 1.388 ± 0.058 1.282 ± 0.071 1.151 ± 0.051 0.940 ± 0.061 1.03 ± 0.061 1.179 ± 0.047
MS = multiple sclerosis; SLE = systemic lupus erythematosus; RA = rheumatoid arthritis; CIS = Clinically Isolated Syndrome; GBS = Guillain--
Barre Syndrome; apoA-I = apolipoproteinA-I.
Data are means ± SD.* No significant differences, multivarite ANOVA, P = 0.755(P > 0.05). There was no significant effect of age on serum apoA-
I levels in different disease groups. ** Significantly different, multivarite ANOVA. P = 0.04(P < 0.05). There was significant effect of sex on serum 
apoA-I levels. ***Significantly different, multivarite ANOVA. P < 0.001. There was significant effect of gender on serum apoA-I levels.Zhang et al. Lipids in Health and Disease 2010, 9:34
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0.064 g/L) showed lower serum apoA-I levels than MS
patients (P = 0.002). In this study, female SLE patients had
the lowest serum apoA-I levels, female MS patients had
the highest serum apoA-I levels (Figure 1).
For male patients (Table 2), male MS patients (1.263 ±
0.075 g/L) had significantly higher serum apoA-I levels
than male RA patients (0.963 ± 0.102 g/L; P = 0.000),
male SLE patients (0.979 ± 0.106 g/L; P = 0.000) and male
healthy subjects(1.112 ± 0.070 g/L; P = 0.001) (Figure 2).
There was no significant different serum apoA-I levels
among patients with CIS (1.422 ± 0.091 g/L; P = 0.177),
GBS (1.260 ± 0.093 g/L; P = 0.978), viral encephali-
tis(1.062 ± 0.080 g/L;P = 0.067) and healthy subjects
(1.112 ± 0.070 g/L; P = 0.142).
Finally, we compared serum apoA-I between male and
female in each disease group (Table 3). The results
showed that serum apoA-I levels was much higher in
female MS patients (1.523 ± 0.082 g/L) and female RA
patients (1.120 ± 0.042 g/L) than the corresponding male
MS patients (1.262 ± 0.087 g/L; P = 120.033) and male RA
patients (0.948 ± 0.049 g/L; P = 120.012) (Figure 3).
Discussion
In this study, we found age at onset have a significantly
effect on serum apoA-I levels in MS patients relative to
other lipid indicators (TG, HDL-C, LDL-C, apoB100),
which show that apoA-I is not only associated with serum
lipid metabolism, but with the pathogenesis of MS. Shore
et al. considered apoA-I was significantly more concen-
Figure 1 Comparison of serum apoA- I levels in entire female pa-
tients (black star symbol) comparison between MS and other 
groups, P < 0.01; (flag symbol) comparison between healthy con-
trols and SLE patients, P < 0.001.
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Table 2: Analysis of serum apoA-I in all male or female patients.
MS CIS GBS Viral 
encephalits
SLE RA Healthy 
controls
Female 32 38 28 26 22 20 27
Mean age ± 
SD*
35.7 ± 14.2 31.2 ± 17.3 29.6 ± 19.9 27.2 ± 13.6 31.4 ± 8.57 35.1 ± 7.75 38.1 ± 14.3
apoA-I (g/L) 1.516 ± 0.057 1.368 ± 0.073 1.321 ± 0.101 1.243 ± 0.064 0.897 ± 0.068 1.107 ± 0.072 1.230 ± 0.062
P** 0 0.114 0.097 0.002 0.000 0.000 0.001
Male 28 19 10 25 14 15 32
Mean age ± 
SD*
36.0 ± 15.6 40.7 ± 18.5 39.9 ± 19.7 30.1 ± 13.8 31.9 ± 13.7 37.9 ± 12.1 33.8 ± 4.11
apoA-I (g/L) 1.263 ± 0.075 1.422 ± 0.091 1.260 ± 0.093 1.062 ± 0.080 0.979 ± 0.106 0.963 ± 0.102 1.112 ± 0.070
P** 0 0.954 0.194 0.001 0.000 0.000 0.001
Data are means ± SD. * Significant different, multivarite ANOVA, P = 0.159 (P > 0.05). There was no significant effect of age on female or male 
serum apoA-I levels in different disease groups. **Compared serum apoA-I levels of between male/female MS patients and male/female 
patients in other groups, patients with autoimmune demyelinating diseases had higher serum apoA-I levels than other patients and healthy 
subjects.
Figure 2 Comparison of serum apoA- I levels in entire male pa-
tients (black star symbol) comparison between MS and other 
groups, P < 0.01.
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trated during active phase of the EAE (experimental aller-
gic encephalomyelitis, a highly relevant model of MS)
than untreated controls [18]. Similar to the Shore ea al,
our research showed increased serum apoA-I levels in
MS patients and other autoimmune demyelinating dis-
ease (CIS, GBS) whether male and female patients.
Recently, Gaillard et al conformed that the decreasing
CSF (cerebral spinal fluid) apo E (apolipoprotein E) con-
centrations in MS patients as apoE was postulated to be a
major lipid carrier protein [23], therefore, we wonder if
the CSF apoA-I concentrations would be increased in MS
patients, our next task is to conform the hypothesis.
The imbalance between pro-inflammatory cytokines
and anti-inflammatory cytokines would lead to autoim-
mune diseases such as RA, MS, SLE, atherosclerosis [24-
27], these cytokines production were modulaed by con-
tact-mediated induction between monocytes and stimu-
lated T lymphocyte. ApoA-I bound the stimulating factor
at the surface of T lymphocytes, hampered the binding of
stimulated T lymphocytes with its specific receptor at
monocyte surface, thus inhibited the production of pro-
inflammatory cytokines including TNF-α and IL-1 [6,28].
Therefore, some researchers believed serum apoA-I con-
centrations should be declined during active phase of
autoimmune diseases, and has played an important role
in anti-inflammation, such as RA, SLE [29-31]. Consisted
with above findings, in our study, serum apoA-I levels in
RA and SLE patients were significantly lower than
healthy subjects. It is interesting that MS patients had the
highest serum apoA-I levels contrary to the hypothesis of
above studies.
The reason remained unknown, but some emerging
evidence that may explain this phenomenon. Some
reports considered serum apoA-I was an inhibitory factor
as a "negative" acute-phase protein, they suggested that
apoA-I might be transported and get into the "leaky"
blood-brain barriers by cerebral endothelial cells, and
proposed apoA-I could enter the demyelinating nerve to
Table 3: Analysis of serum apoA-I between male and female patients in different diseases.
Group Mean age ± SD 
(years)
apoA-I(g/L) P
MS Male (n = 28) 36.0 ± 15.6 1.2620.087 0.033*
Female (n = 32) 35.7 ± 14.2 1.5230.082
CIS Male (n = 38) 40.7 ± 18.5 1.4070.082 0.082
Female (n = 19) 31.2 ± 17.3 1.3700.082
GBS Male (n = 28) 39.9 ± 19.7 1.2650.086 0.876
Female (n = 10) 29.6 ± 19.9 1.2880.116
viral encephalitis Male (n = 25) 30.1 ± 13.8 1.0760.060 0.080
Female (n = 26) 27.2 ± 13.6 1.2210.058
SLE Male (n = 14) 31.9 ± 13.7 0.9840.067 0.296
Female (n = 22) 31.4 ± 8.57 0.8930.053
RA Male (n = 15) 37.9 ± 12.1 0.9480.049 0.012*
Female (n = 20) 35.1 ± 7.75 1.1200.042
Healthy controls Male (n = 32) 33.8 ± 4.11 1.1170.075 0.277
Female (n = 27) 38.1 ± 14.3 1.2410.082
Data are means ± SD.* Significantly different, multivarite ANOVA, P = 0.033 (P < 0.05), there was significant effect of gender on female and 
male serum apoA-I levels in MS patients.
Figure 3 Comparison of serum apoA- I levels between female and 
male patients.
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regenerate impaired nerve and myelin from plasma when
the blood-nerve barrier was disrupted after injury
[32,33]. In recent years, some researchers conformed that
astrocytes generated apoA-I and apoE in rat, apoA-I facil-
itated translocation of newly synthesized cholesterol and
phospholipid to cytosol to form the lipid-protein com-
plex particles as an initial event in cholesterol trafficking
for the assembly of HDL, and found cholesterol efflux
from rat astrocytes induced by apoA-I and apoE. In CNS,
apoA-I could modulate transport of cholesterol and
reduce CNS impairments by activating the brain lecithin
cholesterol acyl transferase (LCAT) [34-36]. They found
apoA-I had increased 26-fold in rat homogenates of
regenerating sciatic nerves within 3 weeks after injury
[35]. Therefore, a large number of serum apoA-I synthe-
sized by liver will be albe to meet the remyelination dur-
ing acute phase of MS.
In the study, our data showed elevated serum apoA-I
concentrations in MS patients may be an important fea-
ture that is different from other autoimmune diseases
which had significantly reduced serum apoA-I levels
(such as RA and SLE). In order to clarify the effect of
CNS inflammatory response on serum apoA-I levels, we
compare neuroinflammation patients with MS patients,
This study further confirmed that, compared to other
CNS inflammatory diseases, the imbalance between
demyelination and regeneration in MS patients may be
related to elevated serum apoA-I concentrations.
Finally, the results indicated that female MS patients
had significant higher serum apoA-I levels than male MS
patients, but this phenomenon have not been found in
other demyelinating diseases. The reason remained
unknown, but it may be associated with the greater sus-
ceptibility and incidence of female MS patients.
Conclusion
MS patients had the highest serum apoA-I levels com-
pared with other disease groups and healthy control, and
female MS patients had a significant higher levels than
male MS patients. Then the following work should be
done to expose the reason for our results, determine the
CSF apoA-I levels in MS patients and discuss relationship
between serum/CSF apoA-I and anti-inflammatory
cytokines.
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